રોસરી બાયોટેક શેરની કિંમત

Specialty Chemicals company Rossari Biotech announced Q4FY26 & FY26 results Q4FY26 Standalone Financial Highlights: Revenue from Operations: Rs 5,161.38 million in Q4FY26, compared to Rs 4,506.58 million in Q3FY26 (up 14.53% QoQ) and Rs 4,266.53 million in Q4FY25 (up 20.97% YoY). કુલ ઇન્કમ: Q3FY26 માં ₹4,517.99 મિલિયન (19.27% QoQ સુધી) અને Q4FY25 માં ₹4,290.49 મિલિયન (25.59% YoY સુધી) ની તુલનામાં Q4FY26 માં ₹5,388.67 મિલિયન. Profit After Tax: Rs 547.30 million in Q4FY26, compared to Rs 306.26 million in Q3FY26 (up 78.70% QoQ) and Rs 323.64 million in Q4FY25 (up 69.11% YoY). Basic EPS: Rs 9.88 in Q4FY26, compared to Rs 5.53 in Q3FY26 (up 78.66% QoQ) and Rs 5.85 in Q4FY25 (up 68.89% YoY). Q4FY26 Consolidated Financial Highlights: Revenue from Operations: Rs 6,848.62 million in Q4FY26, compared to Rs 5,816.80 million in Q3FY26 (up 17.74% QoQ) and Rs 5,795.62 million in Q4FY25 (up 18.17% YoY). કુલ ઇન્કમ: Q3FY26 માં ₹5,821.89 મિલિયન (20.91% QoQ સુધી) અને Q4FY25 માં ₹5,813.53 મિલિયન (21.08% YoY સુધી) ની તુલનામાં Q4FY26 માં ₹7,039.27 મિલિયન. Profit After Tax: Rs 459.67 million in Q4FY26, compared to Rs 327.74 million in Q3FY26 (up 40.25% QoQ) and Rs 344.44 million in Q4FY25 (up 33.45% YoY). Basic EPS: Rs 8.30 in Q4FY26, compared to Rs 5.91 in Q3FY26 (up 40.44% QoQ) and Rs 6.22 in Q4FY25 (up 33.44% YoY). નાણાંકીય વર્ષ 26 સ્ટેન્ડઅલોન ફાઇનાન્શિયલ હાઇલાઇટ્સ: કામગીરીમાંથી આવક: નાણાંકીય વર્ષ 26 માં ₹ 17,520.66 મિલિયન, નાણાંકીય વર્ષ 25 માં ₹ 14,316.28 મિલિયન (22.38% વર્ષ સુધી). કુલ ઇન્કમ: નાણાંકીય વર્ષ 26 માં ₹ 17,790.75 મિલિયન, નાણાંકીય વર્ષ 25 માં ₹ 14,373.70 મિલિયનની તુલનામાં (વર્ષમાં 23.77% સુધી). ટૅક્સ પછીનો નફો: નાણાંકીય વર્ષ 26 માં ₹1,428.38 મિલિયન, નાણાંકીય વર્ષ 25 માં ₹1,147.42 મિલિયનની તુલનામાં (વર્ષમાં 24.49% સુધી). Net Cash Flows Generated from Operating Activities: Rs 587.29 million in FY26, compared to Rs 921.98 million in FY25 (down 36.30% વાય). મૂળભૂત ઇપીએસ: નાણાંકીય વર્ષ 25 માં ₹ 20.75 ની તુલનામાં નાણાંકીય વર્ષ 26 માં ₹ 25.79 (વર્ષમાં 24.29% સુધી). Dividend: The Board recommended a Final Dividend of 25% (i.e. Rs 0.50/- per share) on Equity Shares of Face Value of Rs 2/- each. નાણાંકીય વર્ષ 26 એકીકૃત નાણાંકીય વિશેષતાઓ: કામગીરીમાંથી આવક: નાણાંકીય વર્ષ 26 માં ₹ 23,963.65 મિલિયન, નાણાંકીય વર્ષ 25 માં ₹ 20,802.94 મિલિયન (વર્ષના 15.19% સુધી) ની તુલનામાં. કુલ ઇન્કમ: નાણાંકીય વર્ષ 26 માં ₹ 24,187.43 મિલિયન, નાણાંકીય વર્ષ 25 માં ₹ 20,843.03 મિલિયનની તુલનામાં (વર્ષમાં 16.05% સુધી). ટૅક્સ પછીનો નફો: નાણાંકીય વર્ષ 26 માં ₹1,492.13 મિલિયન, નાણાંકીય વર્ષ 25 માં ₹1,363.78 મિલિયનની તુલનામાં (વર્ષમાં 9.41% સુધી). Net Cash Generated from Operating Activities: Rs 650.68 million in FY26, compared to Rs 1,374.43 million in FY25 (down 52.66% YoY). મૂળભૂત ઇપીએસ: નાણાંકીય વર્ષ 25 માં ₹ 24.66 ની તુલનામાં નાણાંકીય વર્ષ 26 માં ₹ 26.95 (વર્ષમાં 9.29% સુધી). Business Highlights: Capacity Addition Project: The Company is re-evaluating its investment plan for the proposed capacity expansion project. Implementation is rescheduled and expected to be undertaken in a phased manner over the next two years. New R&D; Facility: A new Research and Development Facility has been set up at Navi Mumbai (Khairane MIDC). The existing R&D; facility at IIT Bombay is being relocated to this new location to enhance innovation and product development capabilities. Asset Monetization: During Q4FY26, the Parent Company sold its Kanjurmarg Office for a consideration of Rs 250 million, resulting in a net gain of Rs 192.67 million. International Expansion: Rossari (Singapore) Pte Ltd was incorporated on December 18, 2025, as part of the Company's global outreach. New Director Appointment: Mr. Udeypaul Singh Gill was appointed as an Additional Director (Non-Executive, Independent) for a term of three years effective from April 28, 2026. પરિણામની PDF

• ટ્રેન્ડલાઇન
• 1 મહિના 3 અઠવાડિયા પહેલાં

Specialty Chemicals company Rossari Biotech announced Q3FY26 results Revenue from operations grew 13% to Rs 581.7 crore as compared to Rs 512.7 crore. EBITDA ₹64.8 કરોડથી 6% થી ₹68.9 કરોડ સુધી સુધારેલ છે. 12.6% સામે 11.8% પર EBITDA માર્જિન. પીએટી ₹31.7 કરોડથી 3% વધીને ₹32.8 કરોડ થયો છે. ઇપીએસ (ડાયલ્યુટેડ) ₹ 5.7 સામે ₹ 5.9 હતું. Edward Menezes, Promoter & Executive Chairman, & Sunil Chari, Promoter & Managing Director, said: “We delivered healthy YoY growth in Q3 FY26 despite a softer domestic demand environment during the quarter. Consolidated revenues grew by 13% YoY, supported by a balanced contribution across business segments and continued traction in our international operations. HPPC recorded a YoY growth of 11% during the quarter, reflecting stable demand amid a softer domestic environment. TSC delivered a growth of 18% YoY, while AHN grew by 39% YoY during the quarter, together providing support to overall growth. The diversified performance across segments helped offset moderation in select end-markets. Exports continued to support overall performance, driven by focused efforts to deepen relationships in key geographies and expand our customer base. Profitability was impacted by ongoing investments in capacity expansion, product development and market-seeding initiatives. These investments are intended to strengthen our long-term competitive positioning, and we remain confident that operating leverage, scale benefits and an improving product mix will support margin improvement over time. Our phased capacity expansion program across verticals continues to progress well, enhancing our manufacturing capabilities. Additionally, we are pleased to announce that the Board has granted in-principle approval to set up greenfield specialty chemicals manufacturing facilities in the Kingdom of Saudi Arabia (KSA).These expansions will support the strategic growth of the Company by improving supply capabilities, accelerating speed-to-market and strengthening the Company’s position as a major player in manufacturing of specialty chemicals. The Project progress will be subject to customary evaluations and necessary regulatory / statutory approvals and is intended to be funded by way of equity, debt, internal accruals, or a combination of these financing means. Looking ahead, we remain focused on disciplined execution, customer-led innovation and sustainable value creation. Supported by strong R&D; capabilities and expanding capacities, we are well-positioned to navigate near-term volatility and deliver consistent, profitable growth for all our stakeholders.” Result PDF

• ટ્રેન્ડલાઇન
• 5 મહિના પહેલાં

Specialty Chemicals company Rossari Biotech announced Q2FY26 results Revenue from operations grew 18% to Rs 586.1 crore as compared to Rs 498.4 crore. EBITDA ₹65.9 કરોડથી 9% થી ₹71.9 કરોડ સુધી સુધારેલ છે. 13.2% સામે 12.3% પર EBITDA માર્જિન. પીએટી ₹35.3 કરોડથી 5% વધીને ₹36.9 કરોડ થયો છે. ઇપીએસ (ડાયલ્યુટેડ) ₹ 6.4 સામે ₹ 6.7 હતું. Edward Menezes, Promoter & Executive Chairman, & Sunil Chari, Promoter & Managing Director, said: “We delivered healthy revenue growth of 18% YoY in Q2 FY26, led by broad-based volume expansion across our key segments. The HPPC, TSC, and AHN businesses grew by 16%, 21%, and 29% respectively, reflecting the continued strength of our diversified portfolio and the focused execution by our teams. On the export front, we are proud to have expanded our global operations, with several geographies emerging as key drivers of future growth. અમે નવા અને હાલના ભૌગોલિક ક્ષેત્રોમાં નવા ગ્રાહકોને લક્ષ્યાંકિત કરીને અને અમારા ભાગીદારો સાથે અમારા વૉલેટ શેરને વધારીને અમારા નિકાસ બજારોમાં મજબૂત પ્રદર્શન નોંધાવ્યું છે. ત્રિમાસિક માટે, નિકાસમાં 36% YoY અને H1 માં વધારો થયો છે. મુખ્ય આંતરરાષ્ટ્રીય બજારોમાં ગ્રાહકની ઊંડાણપૂર્વકની સંલગ્નતા દ્વારા સંચાલિત તે 27% સુધીમાં વધારો થયો છે. Now exports contribute almost 28% of our overall sales. While robust volumes supported the top line, profitability remained steady owing to subdued pricing and ongoing investments in seeding new business opportunities. We are confident that as these initiatives begin to contribute to revenues, profitability will improve progressively going forward. With a diversified product portfolio, agile manufacturing capabilities, new capacity additions and a strong balance sheet, we believe we are well-positioned to capitalize on emerging opportunities and drive healthy growth for the foreseeable future. As a growth-focused Company, we remain committed to innovation, continuously developing tailored solutions that meet the evolving needs of our customers. We are working towards expanding our global footprint through our own manufacturing set up and sales & distribution network overseas. This approach strengthens our confidence in delivering sustainable operational and financial performance while creating long-term value for all our stakeholders.” Result PDF

• ટ્રેન્ડલાઇન
• 8 મહિના પહેલાં